Bayer: ‘Guidelines in Practice’ commissioned videos not ruled disguised promotion for Xarelto (AUTH/3322/3/20)

📅 2020 | 🖉 Dr Anzal Qurbain
📊

Key facts

Case numberAUTH/3322/3/20
CompanyBayer
ComplainantA concerned UK health professional
MedicineXarelto (rivaroxaban)
MaterialTwo commissioned videos hosted on the ‘Guidelines in Practice’ website
AllegationDisguised promotion
Clause(s) consideredClause 12.1
DecisionNo breach
Complaint received10 March 2020
Case completed17 June 2020
Applicable Code year2019
AppealNo appeal

Download the full case report (PDF)


Reviewed by Dr Anzal Qurbain (FFPM) — ABPI Final Signatory

🤖

Got a question about this case?

Ask one of our 13 specialist ABPI advisors — instant answers, 24/7.

Ask AskAnzal AI
🎬 Expert Video Walkthrough
🎬
Video walkthrough — coming for members
Subscribe now and get expert video analysis for every case as we publish them.
Subscribe — from £299/yr
📋

What happened

  • A UK health professional complained about two videos hosted on the ‘Guidelines in Practice’ website: ‘Secondary event prevention and risk stratification in patients with symptomatic peripheral arterial disease’ and ‘Secondary event prevention and risk stratification in patients with stable coronary artery disease’.
  • The videos were commissioned by Bayer and linked to Xarelto (rivaroxaban) prescribing information.
  • The complainant alleged the videos were disguised promotion because the disclaimers did not explicitly state the content was promotional; the only “clue” was the prescribing information link and wording such as ‘commissioned’ and ‘suggested the topic’.
  • The PMCPA asked Bayer to consider the requirements of Clause 12.1.
  • Bayer said the webpages were commissioned and certified for promotional use, included prominent ‘Commissioned by Bayer plc’ wording at the top, a prominent ‘View prescribing information’ link, and a detailed sponsorship declaration at the bottom; similar disclosures and the Bayer logo also appeared within the videos.
⚖️

Outcome

  • No breach of the Code was ruled.
  • No breach of Clause 12.1 (disguised promotion) was ruled.
🔒

Unlock the full case analysis

Members get the complete breakdown — Clauses, Sanction, Signatory Lens, Audit checklist, and 3 Key Questions.

Best value
£249/year
Annual — save £99
or
£29/mo
Monthly
Join Now — Instant Access

⭐ Business Intelligence Access

See the full compliance picture for every pharma company

291 Company Intelligence Reports — breach patterns, appeal history, industry ranking, PDF export.

Request Access →
⭐ Flagship Programme

AQP Flagship Path — the complete UK ABPI signatory programme

12 modules. 12 weeks. Final Signatory readiness. The industry standard for ABPI Code signatories — £995 + VAT.

Enrol — AQP Path Learn more

📰 Weekly PMCPA Case Breakdown

One real case. One key lesson. Every week — free.

Subscribe Free
🎓 AQP Training